Escitalopram updated on 07-01-2025

Ventricular septal defect

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7472
R22338		 Anderson, 2020 Ventricular septal defect (VSD) – perimembranous type 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.87 [0.31;2.45] -/-   0/- - -
ref
S7353
R21567		 Wemakor, 2015 Ventricular septal defect 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.62 [0.13;2.85] C 2/11   6,165/23,239 6,167 11
ref
S6015
R15508		 Jimenez-Solem (Controls unexposed, NOS), 2012 Ventricular septal defects 1st trimester population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.51 [0.03;8.22] C
excluded (control group) 		0/293   2,803/843,797 2,803 293
ref
S6020
R15604		 Jimenez-Solem (Controls unexposed, sick), 2012 Ventricular septal defects 1st trimester population based cohort retrospective unexposed, sick Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 0.14 [0.01;2.47] C 0/293   9/806 9 293
ref
S6245
R16530		 Malm, 2011 Ventricular septal defects 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 1.47 [0.73;2.97] 8/441   5,465/628,607 5,473 441
ref
Total 4 studies 1.01 [0.56;1.84] 11,649 745
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 0.87[0.31; 2.45]--29%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Wemakor, 2015Wemakor, 2015 0.62[0.13; 2.85]6,1671114%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Jimenez-Solem (Controls unexposed, sick), 2012Jimenez-Solem, 2012 1 0.14[0.01; 2.47]92934%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: critical Malm, 2011Malm, 2011 1.47[0.73; 2.97]5,47344153%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (4 studies) I2 = 11% 1.01[0.56; 1.84]11,6497450.05.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.70[0.08; 5.87]5,48273459%NAJimenez-Solem (Controls unexposed, sick), 2012 Malm, 2011 2 case control studiescase control studies 0.78[0.33; 1.84]6,167110%NAAnderson, 2020 Wemakor, 2015 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.14[0.66; 1.96]11,6404520%NAAnderson, 2020 Wemakor, 2015 Malm, 2011 3 unexposed, sickunexposed, sick 0.14[0.01; 2.47]9293 -NAJimenez-Solem (Controls unexposed, sick), 2012 1 Tags Adjustment   - No  - No 0.44[0.12; 1.71]6,1763040%NAWemakor, 2015 Jimenez-Solem (Controls unexposed, sick), 2012 2   - Yes  - Yes 1.25[0.70; 2.23]5,4734410%NAAnderson, 2020 Malm, 2011 2 Monotherapy   - no or not specified  - no or not specified 1.47[0.73; 2.97]5,473441 -NAMalm, 2011 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.78[0.33; 1.84]6,167110%NAAnderson, 2020 Wemakor, 2015 2   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.14[0.01; 2.47]9293 -NAJimenez-Solem (Controls unexposed, sick), 2012 1 Unexposed sick   - intermediate history of illness/tre ...  - intermediate history of illness/treatment (3-12 months before pregnancy) 0.14[0.01; 2.47]9293 -NAJimenez-Solem (Controls unexposed, sick), 2012 1 All studiesAll studies 1.01[0.56; 1.84]11,64974511%NAAnderson, 2020 Wemakor, 2015 Jimenez-Solem (Controls unexposed, sick), 2012 Malm, 2011 40.05.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.43.41.7430.000Anderson, 2020Wemakor, 2015Jimenez-Solem (Controls unexposed, sick), 2012Malm, 2011

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 6015

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.11[0.65; 1.89]14,4437450%NAAnderson, 2020 Wemakor, 2015 Jimenez-Solem (Controls unexposed, NOS), 2012 Malm, 2011 4 unexposed, sick controlsunexposed, sick controls Out of scale0.14[0.01; 2.47]9293 -NAJimenez-Solem (Controls unexposed, sick), 2012 10.510.01.0